Core Insights - On September 18, Hanbang Technology experienced a decline of 1.69% with a trading volume of 53.52 million yuan [1] - The company had a net financing buy of -0.94 million yuan on the same day, with a total financing and securities balance of 92.89 million yuan [1] Financing Overview - On September 18, Hanbang Technology had a financing buy of 10.95 million yuan, with a current financing balance of 92.89 million yuan, accounting for 12.21% of the circulating market value [1] - There were no shares repaid or sold in the securities lending market on that day, resulting in a securities lending balance of 0.00 yuan [1] Company Profile - Hanbang Technology, established on October 28, 1998, is located in Huai'an Economic and Technological Development Zone, Jiangsu Province [1] - The company specializes in providing separation and purification equipment, consumables, application technology services, and related technical solutions for the pharmaceutical and life sciences sectors [1] - The revenue composition includes: 70.99% from small molecule drug separation and purification equipment, 22.94% from large molecule drug separation and purification equipment, and 6.07% from other sources [1] Financial Performance - As of June 30, the number of shareholders for Hanbang Technology was 9,372, a decrease of 48.43% from the previous period [2] - The average circulating shares per person increased by 93.92% to 1,764 shares [2] - For the first half of 2025, the company reported a revenue of 349 million yuan, a year-on-year increase of 5.99%, while the net profit attributable to the parent company was 27.80 million yuan, a decrease of 26.24% year-on-year [2] - As of June 30, the largest circulating shareholder was Dongfanghong Medical Upgrade Stock Initiation A (015052), holding 483,700 shares as a new shareholder [2]

Core Insights - Hanbang Technology's stock price increased by 0.04% on September 17, with a trading volume of 29.5371 million yuan [1] - The company experienced a net financing outflow of 2.5878 million yuan on the same day, with a total financing and securities balance of 93.8258 million yuan [1] - As of June 30, 2025, Hanbang Technology reported a revenue of 349 million yuan, a year-on-year increase of 5.99%, while net profit decreased by 26.24% to 27.7976 million yuan [2] Financing and Trading Data - On September 17, Hanbang Technology had a financing buy amount of 2.8171 million yuan and a financing repayment of 5.4048 million yuan, resulting in a net financing buy of -2.5878 million yuan [1] - The current financing balance of 93.8258 million yuan accounts for 12.12% of the company's market capitalization [1] - No shares were sold or repaid in the securities lending market on September 17, with a total securities lending balance of 0 [1] Shareholder Information - As of June 30, 2025, the number of shareholders for Hanbang Technology was 9,372, a decrease of 48.43% from the previous period [2] - The average number of circulating shares per shareholder increased by 93.92% to 1,764 shares [2] - The largest circulating shareholder is Dongfanghong Medical Upgrade Stock Initiation A (015052), holding 483,700 shares as a new shareholder [2] Business Overview - Hanbang Technology, established on October 28, 1998, specializes in providing separation and purification equipment, consumables, application technology services, and related technical solutions for the pharmaceutical and life sciences sectors [1] - The revenue composition of the company includes 70.99% from small molecule drug separation and purification equipment, 22.94% from large molecule drug separation and purification equipment, and 6.07% from other sources [1]

中信证券股份有限公司（以下简称"中信证券"或"保荐人"）作为江苏汉 邦科技股份有限公司（以下简称"汉邦科技"或"公司"或"上市公司"）首次 公开发行股票并在科创板上市的保荐人。根据《证券发行上市保荐业务管理办 法》、《上海证券交易所科创板股票上市规则》等相关规定，中信证券履行持续 督导职责，并出具本持续督导半年度跟踪报告。 一、持续督导工作概述 1、保荐人制定了持续督导工作制度，制定了相应的工作计划，明确了现场 检查的工作要求。 2、保荐人已与公司签订保荐协议，该协议已明确了双方在持续督导期间的 权利义务，并报上海证券交易所备案。 中信证券股份有限公司 关于江苏汉邦科技股份有限公司 2025 年半年度持续督导跟踪报告 3、本持续督导期间，保荐人通过与公司的日常沟通、现场回访等方式开展 持续督导工作，并于 2025 年 8 月 25 日对公司进行了现场检查。 4、本持续督导期间，保荐人根据相关法规和规范性文件的要求履行持续督 导职责，具体内容包括： （1）查阅公司章程、三会议事规则等公司治理制度、三会会议材料； （2）查阅公司财务管理、会计核算和内部审计等内部控制制度； （3）查阅公司与控股股东、实际控制人及其 ...

Core Insights - Jiangsu Hanbang Technology Co., Ltd. has made significant progress in three patent infringement lawsuits against Stora Enso Sweden AB, with two patents related to "chromatography columns" and "separation medium slurry tanks" declared invalid by the National Intellectual Property Administration of China [1][2] - The third lawsuit concerning the "column filling method" resulted in a ruling by the Nanjing Intermediate People's Court that Hanbang Technology did not infringe, and the case is currently awaiting review by the Supreme People's Court [1][2] - The lawsuits highlight Hanbang Technology's strength in independent innovation within the chromatography technology sector and provide a reference for domestic high-end pharmaceutical equipment companies to overcome international patent barriers [1] Company Overview - Hanbang Technology is a high-tech enterprise focused on chromatography technology, with over 20 years of experience in the separation and purification equipment field [2] - The company has developed a core technology system termed "one heart, two cores, multiple uses," which includes chromatography column technology and system integration and application technology, covering a full product line for drug separation and purification from small to large molecules [2] - Hanbang Technology's products have been sold to over 2,000 customers domestically and internationally, emphasizing its market presence and commitment to innovation [2] Legal Context - Stora Enso previously filed lawsuits against Hanbang Technology, claiming infringement of three invention patents, with total compensation claims exceeding 16.5 million yuan [1] - The decisive outcome in the second patent infringement case led to the Supreme People's Court's final ruling to revoke the original judgment and dismiss Stora Enso's claims [1][2] - The ongoing legal proceedings reflect the competitive landscape in the chromatography technology sector and the importance of intellectual property rights for companies like Hanbang Technology [2]

Core Viewpoint - Hanbang Technology (688755.SH) has made progress in three patent infringement lawsuits against Cytiva, with two patents declared invalid by the National Intellectual Property Administration and one case still under review by the Supreme People's Court [1][2]. Group 1: Patent Litigation Progress - Two of the patents involved in the lawsuits have been declared invalid by the National Intellectual Property Administration, leading to the Supreme People's Court overturning the initial ruling that found Hanbang Technology guilty of infringement [1]. - The lawsuit concerning the "column filling method" is still ongoing, with the first instance ruling in favor of Hanbang Technology, but Cytiva has appealed, and the case is currently under review by the Supreme People's Court [1]. Group 2: Company Overview and Market Position - Hanbang Technology has invested over 108 million yuan in R&D from 2022 to 2024, with R&D personnel accounting for over 20% of its workforce [2]. - The company holds a 39.2% market share in the production-grade small molecule liquid chromatography system, leading the domestic market, while its large molecule chromatography system ranks among the top three, breaking the long-standing monopoly of international giants like Danaher and Sartorius [2]. - Hanbang Technology has developed a comprehensive technical system covering chromatography column technology, system integration, and application solutions, with products used in various applications across over 2,000 domestic and international enterprises [2].

Group 1 - The company held its second board meeting on September 11, 2025, where all nine directors attended and agreed to waive the notice period for the meeting [2][3] - Zhang Dabin was elected as the chairman of the second board of directors with unanimous approval [3][6] - The board established several specialized committees, including the audit committee, nomination committee, compensation and assessment committee, and strategy committee, with a term of three years [4][26] Group 2 - The board approved the appointment of Zhang Dabin as the general manager (CEO) of the company, effective immediately [4][27] - The board appointed Tang Yefeng as the secretary of the board, with a term aligned with the board's term [8][28] - The company appointed several vice presidents, including Li Shengying, Tang Yefeng, Jin Xinliang, Liu Genshui, and Yan Zhong, with the same term as the board [11][27] Group 3 - The board approved the appointment of Gu Bin as the financial director, effective immediately [14][27] - The company appointed Xie Yuxin as the securities affairs representative, with a term aligned with the board's term [17][28] - The board approved the addition and revision of certain governance systems to enhance operational standards and protect shareholder rights [19][50]

Core Viewpoint - Hanbang Technology announced the appointment of Mr. Zhang Dabin as the new General Manager (President) of the company [2] Group 1 - The announcement was made on the evening of September 11 [2] - The appointment is expected to influence the company's strategic direction and operational management [2] - Mr. Zhang Dabin's experience and leadership are anticipated to contribute positively to the company's growth [2]

Core Viewpoint - Hanbang Technology announced the appointment of Mr. Xie Yuxin as the company's securities affairs representative [2] Group 1 - The appointment was officially announced on the evening of September 11 [2]

Core Points - The company announced the appointment of Mr. Ge Bin as the Chief Financial Officer [2] Company Summary - The announcement was made on the evening of September 11 [2]

Core Points - The company announced the appointment of Mr. Tang Yefeng as the secretary of the board of directors on the evening of September 11 [2] Company Summary - The company, Hanbang Technology, has made a significant leadership change by hiring a new board secretary [2]